Part,  Chapter, Paragraph

 1   II,     5.  3.  7|        ways to avoid the disease (Boyle et al, 2003).~ ~See Chapter
 2   II,     5.  3.  9|         Oncology 8 (9):773-783.~ ~Boyle P, Autier P, Bartelink H,
 3   II,     5.  3.  9|          M, Heanue M, Colombet M, Boyle P (2007): Estimates of the
 4   II,     5.  4.  2|      Scotland (Morris et al 1997; Boyle et al 2001), followed by
 5   II,     5.  4.  8|    Experimental 13(4), 245. 2001.~Boyle D, Cunningham S, Sullivan
 6   II,     5.  4.  8|          74:S200-S204.~Morris AD, Boyle DI, MacAlpine R, Emslie-Smith
 7   II,     5.  5.  2|    Godfrey M, Townsend J, Surr C, Boyle G and Brooker D (2005):
 8   II,     5. 11.  3|         Diepgen and Mahler, 2002; Boyle et al, 2004).~ ~Non-Melanoma
 9   II,     5. 11.  3|          in the Nordic countries (Boyle and Smans, 2003).~Both basal
10   II,     5. 11.  3|       Greece, Spain and Portugal (Boyle and Smans, 2003).~Melanoma
11   II,     5. 11.  7|         Venereol 2001;81:193-7.~ ~Boyle P, Dorè JF, Autier P, Ringborg
12   II,     5. 11.  7|           Oncol 2004;15(1):5-6.~ ~Boyle P, Smans M (2003): Cancer
13   II,     5. 11.  7|          Severi G, Obsitnikova A, Boyle P. Trends in the incidence
14   II,     9.  3.  1|          than previously thought (Boyle et al 2003). The causes
15   II,     9.  3.  1|     Lancet; 362; 9382; 419-427.~ ~Boyle, P. Robertson, C. Mazzeha,
16  III,    10.  2.  1|     Tobacco Control; 12:360-367~ ~Boyle P, Autier P, Bartelink H,
17   IV,    11.  1.  6| efficiency or increased activity (Boyle, 2007).~ ~Administrative
18   IV,    11.  6.  5|      Medicine 335(12): 891-894.~ ~Boyle S (2007): "Payment by Results